To determine whether thrombospondin-1 is the driving force of dissecting AAA pathogenesis in the absence of LH1, we used TAX2, a CD47-derived cyclic peptide that targets thrombospondin-1, selectively prevents the thrombospondin-1:CD47 interaction and blocks the downstream signaling pathway. The gene discussed is PLOD1; the disease is triple-A syndrome.